Expanded access to NRX-101 for treatment-resistant depression
Part of Mental health clinical trials.
This expanded access program offers the combination of NRX-101 and theta burst transcranial magnetic stimulation (TMS) for people with treatment-resistant depression who cannot participate in a related clinical trial. It aims to provide treatment access while monitoring safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have treatment-resistant depression (tried at least one depression medicine for the current episode that didn't work or caused side effects).
- You are planning to receive a specific type of TMS (theta burst) as part of your usual care.
- You are under the care of a psychiatrist or qualified prescriber who has been trained for this program.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use an acceptable form of birth control.
- You do not have certain medical conditions like unstable diabetes, seizure history, heart disease, or severe kidney or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding the drug NRX-101 to a new type of brain stimulation (TMS) helps adults with depression that hasn't improved with other treatments. You must be new to TMS and have tried at least two antidepressants without success.
This trial studies signs in the brain (biomarkers) during an accelerated form of nerve stimulation to treat depression that hasn’t improved with usual antidepressants. It may help researchers learn who benefits and how to better personalize treatment.
This trial tests whether using brain-related “biomarkers” from your scans to guide rTMS can improve depression that hasn’t responded to at least one antidepressant. It may help by targeting brain circuits linked to depression more precisely.
This trial tests a new brain stimulation treatment (deep brain stimulation, or DBS) for people with hard-to-treat depression. It aims to see if targeting a specific brain area can help when other treatments have failed.
This study tests a new approach for depression: a single day of ultra-accelerated transcranial magnetic stimulation (TMS) combined with one dose of an experimental drug called NRX-101. It aims to see if this combination can quickly improve mood in people with moderate to severe depression.
This study tests a type of brain stimulation called cTBS (continuous theta burst stimulation) applied to a specific part of the brain (the precuneus) to see if it helps with treatment-resistant depression. It aims to provide a new option for people who haven't found relief from standard treatments.
Hear when a new Treatment Resistant Depression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.